[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reproductive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reproductive-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100610200","phase-1-kisspeptin-to-quantify-gnrh-neuronal-function-in-health-and-disease-100610200",false,"NCT07224490","Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease","Inclusion Criteria\n\n* Female (ages 18-45 years) or Male (ages 18-60 years)\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration\n* For women, negative serum hCG pregnancy test\n* For cases, diagnosis of post-covid-19 syndrome\n* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome\n\nExclusion Criteria\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol or the interpretation of results\n* Active use of illicit drugs (not including marijuana)\n* For women,\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* Surgical or natural menopause","ALL","18 Years","60 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.",[26,27,28,29],"Reproductive Disorder","Neurodegeneration","SARS-CoV 2","Long COVID",[31,27,28,32,29],"Reproductive disorder","Kisspeptin","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-03-10",{"date":41,"type":20},"2030-05",{"name":43,"class":44},"Stephanie B. Seminara, MD","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100610668","phase-2-autologous-decidual-like-natural-killer-cells-therapy-for-reproductive-failure-100610668","NCT07230574","Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure","A Prospective, Multicenter, Randomized Controlled Clinical Study on Autologous Decidual-like NK Cells Therapy for Reproductive Failure Associated With Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* Reproductive failure with abnormal endometrial natural killer (NK) cells in menstrual blood;\n* With a clear intention to conceive;\n* Normal ovarian function, or premature ovarian insufficiency with ≥2 high-quality cryopreserved embryos available for transfer;\n* Endometrial thickness measured by transvaginal ultrasound during the periovulatory period ≥7 mm;\n* Body mass index (BMI) between 18 kg\u002Fm² and 28 kg\u002Fm²;\n* Willing to comply with the follow-up plan of this study.\n\nExclusion Criteria:\n\n* Use of progesterone receptor modulators;\n* One of the couple's chromosomal karyotype abnormalities, with no euploid embryo identified via preimplantation genetic testing for aneuploidy;\n* Severe endometriosis or adenomyosis, uterine fibroids affecting uterine cavity morphology, uterine malformations, intrauterine adhesions, or thin endometrium;\n* Uncontrolled autoimmune or endocrine disorders;\n* Contraindications to pregnancy;\n* History of malignant tumors;\n* Participating in other clinical studies;\n* Allergy to blood products.","FEMALE","22 Years","38 Years",{"count":57,"type":20},159,[59],"PHASE2","The aim of this study is to verify the efficacy of in vitro induction of autologous decidual-like NK cells therapy for reproductive failure associated with uterine NK cells abnormalities.",[62,63,26],"Abortion, Missed","Infertility Unexplained",[65,66,67,68],"Recurrent Pregnancy Loss","Repeated Implantation Failure","Unexplained Infertility","Decidual Natural Killer Cells","NOT_YET_RECRUITING","2025-11-13",{"date":72,"type":37},"2025-11-17",{"date":74,"type":20},"2025-11",{"date":76,"type":20},"2028-09",{"name":78,"class":44},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"]